Association between Coexisting Dementia and Mortality in Patients Receiving Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Nationwide Real-world Database Study
Masaki Sogame, Yasutaka Ihara, Shoichiro Yamamoto, Maya Shimasaki, Tomohisa Kurata, Shinji Akiyama · 2026
Read Association between Coexisting Dementia and Mortality in Patients Receiving Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Nationwide Real-world Database Study by Masaki Sogame, Yasutaka Ihara, Shoichiro Yamamoto, Maya Shimasaki, Tomohisa Kurata, Shinji Akiyama (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13639698.txt.
Description
Sogame and colleagues used a large Japanese insurance claims database in 2026 to ask whether dementia worsens survival for lung cancer patients on targeted pill therapy. The drugs, called EGFR inhibitors, are standard first treatment for a common gene-driven lung cancer, but they demand steady self-management at home. Memory and thinking problems could undermine that routine.
More than thirteen thousand patients who started the drugs between 2018 and 2024 were tracked for three-year survival. About two in a hundred had dementia recorded before treatment. That group died at a rate about a third higher than others, even after adjusting for age, health, and daily function. Among patients with dementia, those who could still manage daily life fully fared better. The authors say dementia marks a group needing close attention at treatment start.
Catalog record
| CREATOR | Masaki Sogame, Yasutaka Ihara, Shoichiro Yamamoto, Maya Shimasaki, Tomohisa Kurata, Shinji Akiyama |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |